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Harald von Boehmer‡ and Jan Buer†k
Peripheral T cell tolerance may result from in the TCR-HA 3 IG-HA mice, we have further analyzed
their phenotype by comparing differentially expressedactivation-induced cell death [1], anergy [1], and/or
genes by gene array analysis between anergic, naive, andimmune response modulation by regulatory T cells
freshly activated T cells with the same specificity. CD41[2] . In mice that express a transgenic receptor
T cells with the transgenic TCR-HA receptor, which canspecific for peptide 111–119 of influenza
be identified by the clonotypic 6.5 antibody, were sortedhemagglutinin presented by Ed class II MHC
from either single transgenic TCR-HA mice or doublemolecules as well as hemagglutinin under control
transgenic TCR-HA 3 IG-HA mice as a source of naiveof the immunoglobulin-k promoter, we have found
and anergic T cells, respectively. To obtain freshly ac-that anergic T cells [3] can also have
tivated cells, naive 6.51 cells obtained from RAG-22/2immunoregulatory function and secrete IL-10 [4].
TCR-HA mice were stimulated in vitro for 16 hr by aIn order to obtain information on molecular
mitogenic dose of anti-CD3 antibodies. RNA was pre-mechanisms involved in anergy and
pared from all populations, 32P-labeled cDNA was ob-immunoregulation, we have compared expression
tained by reverse transcription, and cDNA probes werelevels of 1176 genes in anergic, naive, and recently
hybridized to identical replicas of gene array membranesactivated CD41 T cells of the same specificity by gene
(Atlas Mouse 1.2 Array, Clontech). The differential ex-array analysis. The results provide a plausible
pression of 1176 genes was analyzed. The blot analysisexplanation for the anergic phenotype in terms of
of differentially expressed genes is shown in Figure 1.proliferation, provide new information on the
Numerical values of signal strength after background cor-surface phenotype of in vivo-generated anergic CD41
rection (see Materials and methods) are given in TableT cells, and yield clues with regard to new candidate
1. Whenever feasible, duplicate analysis was performed,genes that may be responsible for the restricted
and the values are indicated in Table 1. The differencescytokine production of in vivo-anergized CD41 T
in gene expression between different cells were, as acells. The molecular fingerprints of such T cells
rule, well reproducible. With regard to surface markershould enable the tracking of this small population
expression, i.e., CD4, CTLA-4, PD-1, CD7, TNFR-2,in the normal organism and the study of their role
and Fas-L, it is clear that with the exception of CD7,in immunoregulation.
anergic cells resemble more closely recently activated
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The ligand of PD-1 (PD-L1) has recently been shown to
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detecting differences in RNA content, which can be re-
flected in different protein expression patterns. In the
Results and discussion view of recently published data [2], it should be noted
Surface molecules that the anergic cells are heterogeneous with regard to
In view of the likely physiological significance of the in CD25 expression, which is not included in the analysis;
about 30% of the cells are CD251. With regard to thevivo-generated anergic and regulatory T cells described
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Figure 1
(a) Genes differentially regulated in anergic versus naive CD41 T cells. using Array-Vision software (Version 5.1). To compare density values
Total RNA of in vivo-anergized T cells from TCR 3 Ig-HA and naive among the two cell populations, the level of each gene was
T cells from TCR-HA mice, respectively, were used as templates to normalized to the total of all genes measured (Table 1). One out of
generate specific 32P-labeled cDNA probes for expression array two independent array analyses results are shown. (b) Genes
analysis (Clontech). RT probes were hybridized to individual cDNA differentially regulated in anergic versus activated CD41 T cells. Total
blots overnight and washed, and gene expression was determined RNA of in vivo-anergized T cells from TCR 3 Ig-HA mice and naive T
by exposing the arrays to Phosphor Imaging screens (Fuji) and analyzed cells from Rag-22/2 TCR-HA mice, respectively, were used as
using a Fuji Bas 2500 16-bit image analysis system. Expression templates to generate 32P-labeled cDNA probes for expression array
levels were determined by measuring the spot density for each gene analysis (Clontech). For further details see Figure 1.
analyzed cell surface markers, a combination of PD-1, upregulated with regard to recently activated cells. This
was the first indication that anergic cells also exhibitedCD7, CD28, and CD4 antibodies should be well suited
for the identification of the particular anergic cell type and features typical of resting naive CD41 T cells.
should be able to distinguish it from naive and recently
activated T cells. Regulation of transcription and cytokine secretion
Of special interest was the specific downregulation of
SATB1 in anergic cells with regard to both of the otherSignal transduction
Regarding TCR signaling, proximal signaling molecules, cell types. SATB1 can act as a transcriptional repressor,
but recent evidence suggests that it may regulate thesuch as CD4 and the src-kinase, were overexpressed when
compared to both naive and recently activated HA-spe- expression of multiple gene clusters, either positively or
negatively, by binding to matrix attachment regions thatcific T cells. While these findings could be interpreted
to indicate that anergic cells somehow represent hyperac- are implicated in the loop domain organization of chroma-
tin [6]. SATB1 may, thus, be involved in the control oftivated cells, a closer inspection of the expression levels
of genes encoding intracellular proteins yields a different lineage-specific expression of multiple genes. These may
include cytokine genes or cytokine receptor genes thatpicture; here, several inhibitors of signal transduction, i.e.,
GDP-dissociation inhibitor (GDI), GapIII, or CD31, ex- are differentially expressed in anergic versus naive and
recently activated T cells.hibited levels comparable to naive CD41 T cells but were
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Table 1
Genes regulated in CD41 T cells that might be critical for the induction and maintenance of anergy in vivo.
mRNA Naive Anergic Activated Putative function
Surface antigens
CD4 85 171 30 Expressed on most thymocytes and a subset of mature T cells.
Interacts with MHC class II molecules and participates in T
cell activation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CD7 4 45 22 Expressed early in T cell development and induced upon T cell
7 27 activation. Ligand unknown. Plays a role in the regulation of
integrin expression.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CD18 100 110 27 Common b subunit of LFA-1.
62 55
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CD28 80 115 248 Costimulatory receptor engagement of CD28 either by B-7 or
10 20 by Ab can strongly enhance TCR signaling responses.
Blocking CD28 engagement inhibits T cell activation and
may result in T cell anergy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CD31 71 46 12 ITIM-containing inhibitor of PTK-dependent signal transducers;
13 5 dampens signals transduced by ITAM-containing receptors,
which delays Ca21 mobilization after TCR-ligation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CTLA-4 2 23 11 Coligand on T cells. Binds to B7 on APCs; delivers a negative
15 29 signal leading to cell cycle arrest.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fas-L 6 29 16 Binds to Fas (CD95) and participates in T cell development,
4 13 regulation of immune responses, and T cell-mediated
cytotoxicity. Fas-L inhibits CD4 T cell proliferation, cell cycle
progression, and IL-2 secretion.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Integrin a4 16 28 1 Together with integrin b1, forms the VLA4 receptor for
12 13 fibronectin and VCAM-1. Role in leukocyte adhesion and
migration expressed on the cell surface as a heterodimer with
one of the integrin a chains.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Integrin b1 30 43 17 Together with integrin b1, forms the VLA4 receptor for
13 15 fibronectin and VCAM-1; important in leukocyte adhesion
and migration.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Integrin b7 103 51 6 Expressed on the cell surface as a heterodimer with one of
17 8 the integrin a chains.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PD-1 22 145 68 Induced upon lymphocyte activation. Contains an
4 65 immunoreceptor tyrosine-based inhibitory motif. Involved in
the maintenance of peripheral self-tolerance by serving as a
negative regulator of immune responses.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LFA-1a 31 101 30 Member of the integrin b2 family. Expressed on all leukocytes;
8 18 mediates interactions with ICAM-1,2,3; involved in leukocyte
adhesion and transendothelial migration.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
TNFR-2 44 84 32 Together with TNFR-1, it can induce a context-dependent
17 75 apoptosis or cell activation; lacks a death domain (unlike
TNFR-1 and CD95).
Common signal transduction pathways
Fyn 20 77 21 Member of the Src-kinase family; involved in TCR-stimulated
9 20 signaling and proliferation of T cells.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GapIII 25 19 1 Negative regulator of Ras; Ras is activated by TCR ligation
9 5 and coordinates important signaling pathways for T cell
activation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GDP-diss. 93 82 25 Blocks dissociation of GDP from G proteins, which keeps the
Inh (GDI) G-protein in an inactive state, preventing the activation of
adenylate cyclase. Substrate for caspase-3.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NFkB-Ia/IkB 23 20 86 IkB-nuclear factor of k-light chain protein enhancer in B cells
9 6 inhibitor alpha; blocks NF-kB transition to the nucleus; thus,
it inhibits NF-kB transcription factor.
(continued)
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Table 1
Continued
mRNA Naive Anergic Activated Putative function
Surface antigens
Lck 75 139 48 Membrane-associated Src-family kinase; primarily expressed
23 28 in T cells; involved in early phosphorylation events of T cell
activation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PLCg 25 32 8 Involved in tyrosine kinase-dependent signaling for mitogenic
1.4 1.8 responses; phosphorylated during T cell activation; anergic
Th1 lymphocytes differ in TCR-mediated tyrosine kinase
activity; associated with alterations in PLCg, IP, and
intracellular free calcium.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Calpactin I/pII 242 471 233 Involved in downregulation of phospholipase-A2 (PLA2); forms
CD44/calpactin-I lipid raft complexes that interact with the
underlying cytoskeleton; blocking of PLA2 leads to an inhibition
of IL-2 stimulated PKC stimulation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SLAP 24 45 82 Src-like adaptor protein (SLAP) expressed in T lineage cells;
13 13 inhibits TCR signaling when expressed in the Jurkat T cell line.
Regulators of transcription and translation
ApoE 568 408 9 Antagonizes posttranslational events in mitogen-activated T
cells that are required for the secretion of bioactive IL-2;
thus, inhibits T cell proliferation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
EGR-1 20 89 98 Early growth response protein 1 regulates IL-2 transcription by
16 34 synergistic interaction with the nuclear factor of activated T cells.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
EGR-2 0 25 37 EGR-2 and EGR-3 regulate Fas-L expression in activated T
cells; EGR-2 is likely to play a role in Fas-L upregulation in
lpr/lpr and gld/gld CD4- and CD8-T cells.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
EGR-3 4 24 49 EGR-3 (unlike EGR-1) can directly mediate TCR-induced
transcription of Fas-L; transcription upregulated after TCR
activation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
E74-like 41 44 18 ETS family transcription factor, binds to conserved DNA
factor 1 11 6 sequence domains including the GM-CSF promoter, the IL-2,
and the CD4-enhancer.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SATB1 251 32 430 Represses apoptosis and proliferation-associated genes (e.g.
77 5 PD-1); peripheral CD41 T cells from SATB12/2 mice fail to
proliferate in response to activating stimuli and upregulate
CD44; SATB1 orchestrates temporal/spatial expression of
genes during T cell development.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
YB1 89 86 301 Class II Y-box binding nuclear factor induced by IFNg; regulates
19 17 various genes involved in cell proliferation.
Cytokine signaling
Common g 25 25 655 Shared by multiple cytokine receptors (IL-2, 4, 7, 9, and 15);
chain unresponsiveness in anergic CD41 T cells is due to defective
signaling through the IL-2R g chain.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
IFNg-RII 45 13 7 Receptor subunit for the proinflammatory cytokine IFNg;
2.4 1.1 downregulated upon TCR-stimulation of primary T cells.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
IL-7Ra 70 20 7 Ligand binding part of the IL-7R; defective IL-7 signal
22 9 transduction leads to severe immunodeficiency.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
IL-10 0 6 0 Regulatory cytokine; inhibits macrophage-mediated cytokine
synthesis and proinflammatory T cell-mediated immunity;
inhibits IL-2-mediated proliferation by blocking the degradation
of the cell cycle inhibitor p27kip1.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SOCS-1 1 14 186 Short lived, negative feedback-regulator of cytokine receptor
signaling (e.g. IL-2, IL-4) via the JAK/STAT pathway; deletion
causes perinatal lethality; peripheral T cells in these mice






mRNA Naive Anergic Activated Putative function
Surface antigens
STAT3 2 9 4 Crucial role in cell growth, suppression of apoptosis, and cell
30 34 motility; important role in cytokine receptor signal transduction
(IL-2R, IL-10R).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
STAT6 25 37 81 Activated in response to IL-4 stimulation; critical for the activation
26 26 or enhanced expression of many IL-4 responsive genes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
TGFb-1 65 102 116 Effector cytokine of Th3; increased TGF-b1 production
52 38 correlates with protection and/or recovery from autoimmune
diseases. TGF-b1 and CTLA-4 act together to terminate immune
responses.
Cell cycle/apoptosis/survival
Bag1 40 35 93 Induced by IL-2R binding; in combination with Bcl-2, BAG-1-
14 13 induction is a key event for the antiapoptotic function of IL-2.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bax 32 31 102 Integral membrane protein that promotes apoptosis; its function
9 11 is countered by Bcl-2 and Bcl-XL.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
C-myc 34 14 395 Protooncogene, expression in T cells induced by IL-2R binding
27 8 through STAT5; c-myc, together with cyclin E/CDK2, inhibits
p27kip1 and enables progression through the cell cycle.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ErbB-2 9 4 116 ERBB-2/c-neu/Her-2, oncogene, receptor tyrosine kinase
3 3 involved in DNA repair mechanisms and G1/S-phase
progression. ErbB2 signals reduce p27kip1 stability, thereby
enabling cell cycle progression.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ESP1 protein 221 280 106 GRG protein, interacts with transcription factors, represses
transcription; suppressor of pim1; required for cyclin destruction;
controls anaphase and mitotic exit.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NOTCH-1 29 74 67 Important role in controlling levels of cell death in T cells.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pim1 36 33 169 Protooncogene, protease expressed in primarily in hematopoietic
13 10 cells, implicated in intracellular signaling processes
accompanying lymphocyte activation; induced by IL-2 as well as
CD3 cross linking.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ptp 0 6 1 Protein tyrosine phosphatase-1 associated with Fas (FAP-1);
1 9 inhibits Fas-mediated cell death.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RXR-a s18 25 4 Receptor for all-trans and 9-cis retinoic acids (RAs) that functions
as a transcription factor. RAs inhibit TCR/CD3-mediated
(activation induced) but enhance glucocorticoid-induced
apoptosis in thymocytes. Costimulation of RXR-a leads to
inhibition of RAR-g-mediated apoptosis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RAR-g 0 10 0 Receptor for RAs; functions as a transcription factor (see also
RXR-a).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
P27(kip1) 41 34 7 Tumor suppressor, inhibits activity of cyclin D-, Ep, A-, and
26 14 B-dependent kinases and of cyclin-activating kinases; in
anergic T cells, it inhibits AP-1 transactivation and IL-2
transcription; IL-10 inhibits proliferation by blocking the
downregulation of p27kip1.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
P38-2G4 63 56 303 Nuclear protein that is active in cell cycle control, highly
expressed between G1 and mid S-phase.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PTMA 228 159 331 Prothymosin alpha; nuclear protein required for proliferation;
58 43 induces the unfolding of chromatin fibers.
Differential expression of 1176 mRNA was investigated by cDNA array sample) was determined by subtraction of this background from
hybridization in naive, in vivo-anergized, and recently activated CD41 average density for each spot. All nonflagged array elements (see
T cells. Spot density for each gene was measured as described in Materials and methods) for which the density value was greater than
Materials and methods. Anergic versus naive populations were 1.4 3 the local background were considered well measured and
compared in two independent array experiments. Local backgrounds were included in this table if they were up or downregulated in the
were computed for each spot. Net density (presented in this table studied T cell populations by a factor $1.75 and a density value
after normalization to the total of all mRNA measured for a particular $5 compared to naive and/or recently activated CD41 T cells.
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Figure 2
FACS analysis of intracellular CTLA-4 and
surface PD-1 on in vivo naive, anergic, and
in vitro anti-CD3-activated TCR-HA T cells.
Histograms were obtained by gating on
CD416.51 T cells. Broken lines represent
background staining (I.C. indicates
intracellular, and E.C. indicates extracellular).
Considering cytokine expression, it was previously noted characterized by a weaker activation and tyrosine phos-
phorylation of Janus-associated kinase (Jak)-3 and signalthat these in vivo-generated anergic cells produced little
IL-2, IL-4, and IFNg ex vivo [4]. Generally, downregula- transducers and activators of transcription (Stat)5 and re-
duced DNA binding ability to Stat5-specific elements.tion of IL-2 secretion seems to be one major pathway to
achieve anergy in several in vitro and in vivo models. At
least four molecules that are directly implicated in the Cell proliferation
regulation of IL-2 synthesis and secretion were differen- IL-2, IL-4, and IL-7 have important roles in cell activation
tially regulated in anergic cells when compared to freshly and proliferation, and it is of interest that in anergic cells,
activated cells. YB-1, a transcription factor reported to be the decreased signaling through these receptors results
necessary for stabilizing the mRNA of IL-2, was downreg- in low level expression of c-myc and pim-1, two key
ulated, while ApoE was upregulated as in naive cells. molecules of cell activation and cycle regulation [12]. In
Fas-L as well as CTLA-4 were specifically upregulated addition to the regulation of signaling molecules in com-
in anergic cells when compared to both naive and recently mon with the TCR (e.g., Lck, MAPK-pathway), cytokine
activated T cells. The latter three molecules were re- receptor-specific signaling appears also to be modulated
ported to inhibit the secretion of bioactive IL-2 at differ- at the level of Jak’s and Stat’s when compared to activated
ent levels [7–10]. cells.
Considering proliferation and cell cycle progression, it isPrevious data from our group as well as the present array
obvious that anergic cells more closely resemble the naiveanalysis revealed that both naive and recently activated
than the activated CD41 T cells in that they express highCD41 T cells did not produce any IL-10, whereas ex vivo
levels of the cell cycle inhibitors p27kip1 and ESP-1 [13]anergic cells expressed significant levels of IL-10 mRNA.
and low levels of cell cycle promoters pim-1 [12] andIt is known that IL-10 blocks the IL-2-mediated downreg-
p38–2G4. C-myc, a direct promoter of proliferation [14],ulation of p27kip1 and upregulation of D cyclins in T
is specifically downregulated in anergic cells. In the con-cell activation and entry into the cell cycle [10]. This may
text of these data, it is of interest that recently Boussiotisrepresent another pathway contributing to the anergic
et al. showed direct inhibition of cyclins D and E byphenotype (see below). Also, one additional regulatory
p27kip1, which is also responsible for the defective trans-cytokine, TGF-b1, was detected in all three populations,
activation of AP-1 and IL-2 transcription in anergized Tbut there was no difference between the three popula-
cells [15]. In these in vitro-anergized T cells, p27kip1tions, confirming previous quantitative PCR data (unpub-
levels were specifically upregulated. While these cellslished data). Cytokine signaling pathways seem to repre-
could be rescued upon coculture with a specific antigensent another important target in the regulation of anergy.
and IL-2, our in vivo-anergized T cells differ since theySignal transduction pathways of the IL-2R, IL-4R, and
remain anergic under these conditions.IL-7R are affected by the common g-chain, which was
downregulated in anergic T cells when compared to acti-
vated T cells. The correlation between the regulation of An additional feature regarding cell cycle regulation that
may explain functional differences between in vivo- andthe common g chain and induction of anergy has pre-
viously been described by Grundstrom et al. [11]. The in vitro-anergized cells is the observation that CD28,
c-myc, and ErbB2 levels are downregulated. CD28-medi-anergic cells analyzed in the above mentioned study were
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Figure 3
(a) Interrelationships between differentially regulated genes at the level (b) Interrelationships between differentially regulated genes at the
of TCR signal transduction, regulation of transcription, and cell fate level of cytokine signaling and proliferation in anergic CD41 T cells
in anergic CD41 T cells relative to naive or resting cells. relative to naive or resting cells.
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were incubated in 24-well plates coated with 5 mg/ml anti-CD3 (2C11)ated signaling as well as c-myc and ErbB2 activities were
for 16 hr and then recovered for RNA preparation.reported to block p27kip1 activity and, thus, to permit
entry into the cell cycle [12, 16, 17]. Thus, with the down-
cDNA array proceduresregulation of these three genes in in vivo-anergized CD41 Differential expression of 1176 genes was investigated by cDNA array
cells, p27kip1 has lost its antagonists. Moreover, it was hybridization in naive, recently activated, and in vivo-anergized CD41 T
cells. Total RNA was extracted using Tri-Reagent LS (Molecular Re-shown that upregulation of CTLA-4, as observed in aner-
search Center) according to the manufacturer’s instructions. After agic cells, inhibits progression through the cell cycle by
DNase I digestion for 30 min at 378C, a second extraction with Tri-inhibiting the production of cyclin D3, cyclin-dependent Reagent LS was carried out in order to obtain high quality total RNA.
kinase (cdk)4, and cdk6. This indicates that CTLA-4 Total RNA (3.5 mg) from each population was used as a template for
the specific synthesis of 32P-radiolabeled cDNA probes according to thesignaling inhibits events early in T cell activation both at
manufacturer’s recommendations (Clontech), except that the RT enzymethe IL-2 transcription level as well as at the level of the
was replaced by Superscript II (GIBCO). cDNA probes were subse-IL-2-independent events of the cell cycle [8]. quently hybridized side-by-side to identical gene array membranes con-
taining various mouse cDNAs, nine housekeeping control cDNAs, and
negative controls immobilized on a nylon membrane (a complete list ofOverall, the data indicate that anergic/regulatory T cells
cDNAs and controls immobilized on the Atlas Mouse 1.2 Array fromexhibit a quite unique gene expression program (see Fig-
Clontech can be found at www.clontech.com). After hybridization and
ure 3, Table 1) that should enable one to trace these cells extensive washes, membranes were exposed to Phosphor Imaging
in normal mice and help promote understanding of the screens (Fuji). Radioactivity was detected using a Fuji Bas 2500 16-bit
image analysis system (Fuji).anergic phenotype in terms of proliferation. A closer inves-
tigation of differentially expressed genes involved in regu-
Data analysislating transcription and perhaps cytokine secretion is re-
cDNA array analysis of gene expression was essentially done as de-quired in order to address the regulatory function of these
scribed [19]. Each spot was defined by positioning of a grid of circles
cells that they exhibit both in vivo as well as in vitro over the array image. Spot density for each gene was measured using
(unpublished data). Array-Vision software (Version 5.1, Imaging Research), along with numer-
ous quality control parameters (see Array-Vision manual). Local back-
grounds were computed for each spot. The net density was determinedMaterial and methods by subtraction of this background from the average density for each spot.
Mice Data files generated by Array-Vision were entered into a custom database.
The TCR-HA transgenic mice expressing a TCR-a/b specific for peptide Single spots or areas of the array with obvious blemishes were flagged
111–119 from influenza HA presented by I-Ed are on the Balb/c back- and excluded from subsequent analyses. All nonflagged array elements
ground and have been previously described, as have those on the recom- for which the density value was greater than 1.43 the local background
bination-activating gene (RAG)-22/2 background [18]. Mice expressing were considered well measured. Most obtained results were confirmed
HA under the Igk promoter and enhancer elements are also on the in two independent array analyses (see Table 1). To compare density
Balb/c background. TCR-HA 3 IG-HA mice were bred in our animal values among the different cell populations, the level of each gene was
facility at Necker. normalized to the total of all genes measured for that sample.
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